Gordon Dunn - 09 Dec 2024 Form 4 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Reporting relationship: Chief Financial Officer
Issuer ticker: QNRX
Reported as of: 09 Dec 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Dec 2024, 16:51:56 UTC
Prior SEC filing: 11 Sep 2024
Next SEC filing: 27 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Gordon Dunn

Key filing fact

Gordon Dunn filed Form 4 for Quoin Pharmaceuticals, Ltd. (QNRX) on 10 Dec 2024.

Key facts

This page summarizes Gordon Dunn's Form 4 filing for Quoin Pharmaceuticals, Ltd. (QNRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Dec 2024, 16:51.

Change

Previous filing in this sequence was filed on 11 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

QNRX transaction Derivative

Share Option (Right to Buy)

Award

Transaction value: $0
Shares: +338,994
Change %
Price: $0.000000
Shares after: 338,994
Date: 09 Dec 2024
Ownership: Direct
Underlying class: ADS
Underlying amount: 338,994
Exercise price: $0.7800
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

Footnote F2

The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028.